Search results
Results from the WOW.Com Content Network
The FDA's decision is a win for Lilly, the drug's manufacturer, according to the Associated Press, prices and ways to access drugs like Zepbound and Mounjaro could be affected as a result of the move.
Diabetes treatment Mounjaro has been on the health regulator's shortage list since late 2022, while weight-loss drug Zepbound was added in April as demand far outstripped supply. The limited ...
Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected.
Lilly's drug, tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management, will cease to be in shortage "very soon," CEO David Ricks said in an interview with Bloomberg in Paris.
(Reuters) -All doses of Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are now available, the U.S. Food and Drug Administration's updated shortage list showed on Friday. However ...
A news release from Eli Lilly in June 2024 outlines some concerns surrounding compounded versions of tirzepatide (the active ingredient in Mounjaro and Zepbound), some of which contained bacteria ...
Eli Lilly recently announced plans to sell cheaper, single-dose vials of Zepbound. Fitch noted that many patients are often unaware that their insurance will cover GLP-1 medications.
According to the health regulator's website, 10, 12.5 and 15 milligram doses of the injection will have limited availability, while lower doses of Mounjaro were shown to be available. Eli Lilly ...